What question did this study set out to answer?

The research aims to evaluate the proliferative fraction of prostatic carcinoma under hormonal manipulation using Ki-67.

Determination of the Proliferative Fraction of a Transplantable, Hormone-Dependent, Human Prostatic Carcinoma (PC-82) by Monoclonal Antibody Ki-67: Potential Application for Hormone Therapy Monitoring

View Full Paper

Ask AI

Bookmark

Authors

Assesses the proliferative fraction in a prostatic carcinoma model, suggesting Ki-67 for hormone therapy monitoring.

The research aims to evaluate the proliferative fraction of prostatic carcinoma under hormonal manipulation using Ki-67.
Used PC-82 model for in vivo assessments of tumor cell proliferation
Applied immunoperoxidase method with Ki-67 monoclonal antibody
Evaluated cycling cells before and after testosterone withdrawal and resubstitution
Conducted assessments in BALB/c mice with different hormonal conditions
Proliferative index decreased from 17% to 1% after testosterone withdrawal
Androgen resubstitution increased tumor cell proliferation to 20% within 4 days
Castration led to similar drops in Ki-67-positive tumor cells
Administration of supraphysiologic testosterone did not affect Ki-67 staining

Gallee et al. (1987) studied this question.

View Full Paper

Ask AI

Bookmark